INS and type 2 diabetes mellitus: As a therapeutic class, the GLP-1/GLP-1R agonists have multiple benefits in type 2 diabetes, including improved beta cell function as evaluated by homeostasis model assessment (HOMA)-B analysis [5, 6], improved proinsulin: insulin ratio [6, 7], enhanced first- and second-phase insulin secretion, and improved beta cell sensitivity to glucose [5, 6].